New perspectives in glioma immunotherapy

Area of Science:

• Neuro-oncology
• Immunology
• Cancer therapy

Background:

• Glioblastoma (GBM) frequently relapses post-treatment due to tumor cell infiltration and resistance.
• Current therapies (surgery, radio/chemotherapy) have limitations in eradicating residual GBM cells.

Purpose of the Study:

• To review immunotherapy approaches for glioblastoma.
• To highlight advancements in GBM immunobiology and stem cell research for developing effective treatments.

Main Methods:

• Discussion of active immunotherapy strategies: molecular-defined, GBM cell-based, and dendritic cell-based vaccines.
• Exploration of cytokine-based therapies (interferons, interleukins) via recombinant molecules or gene transfer.
• Review of monoclonal antibodies and genetically modified ligands targeting GBM or neovasculature.
• Consideration of adoptive immunotherapy using in vitro expanded effector cells.

Main Results:

• Immunotherapy aims to eliminate residual GBM cells by targeting them with immune effector cells or antibodies.
• Identifying GBM antigens, receptors, and immune escape mechanisms is crucial for developing new therapeutic targets.
• Various immunotherapy modalities, including vaccines, cytokines, antibodies, and cell-based therapies, are being explored.

Conclusions:

• Immunotherapy holds significant potential to improve outcomes for glioblastoma patients.
• Further research into GBM immunobiology and immune interactions is essential for optimizing immunotherapy protocols.
• Combining immunotherapy with standard treatments may offer a more effective strategy against recurrent glioblastoma.